INITIATING TREATMENT WITH MAYZENT®—A ONCE-DAILY ORAL1
INITIATING TREATMENT WITH MAYZENT®—A ONCE-DAILY ORAL1
Assessments recommended for all patients

BLOOD TESTS
-
CBC
-
CYP2C9 genotype testing*
-
VZV antibody serology
-
LFT (transaminases & bilirubin)

AN OPHTHALMIC EVALUATION
-
Evaluation of the fundus, including the macula
-
If there is any change in vision during treatment, a follow-up evaluation is recommended

AN ECG TEST
-
ECG to determine whether an FDO is recommended

SKIN EXAMINATIONS
-
Prior to or shortly after initiation: skin examination baseline should be obtained†
-
Any suspicious skin lesion observed should be promptly evaluated
*Genotype testing is required to determine the appropriate maintenance dose.
†Skin examinations are not currently covered by the Alongside™ MAYZENT Program.
Assessments recommended for all patients

-
CBC
-
CYP2C9 genotype testing*
-
VZV antibody serology
-
LFT (transaminases & bilirubin)

-
Evaluation of the fundus, including the macula
-
If there is any change in vision during treatment, a follow-up evaluation is recommended

-
ECG to determine whether an FDO is recommended

-
Prior to or shortly after initiation: skin examination baseline should be obtained†
-
Any suspicious skin lesion observed should be promptly evaluated
*Genotype testing is required to determine the appropriate maintenance dose.
†Skin examinations are not currently covered by the Alongside™ MAYZENT Program.
First-dose observation for patients with preexisting
cardiac conditions
An FDO of 6 hours is needed for patients with:
-
Sinus bradycardia (HR <55 BPM)
-
First- or second-degree Mobitz type I AV block
-
A history of myocardial infarction or heart failure
-
Monitoring should continue for 6 hours after the first dose to evaluate for signs and symptoms of bradycardia
-
An ECG should be conducted at the end of the observation period
First-dose observation for patients with preexisting
cardiac conditions
An FDO of 6 hours is needed for patients with:
-
Sinus bradycardia (HR <55 BPM)
-
First- or second-degree Mobitz type I AV block
-
A history of myocardial infarction or heart failure
-
Monitoring should continue for 6 hours after the first dose to evaluate for signs and symptoms of bradycardia
-
An ECG should be conducted at the end of the observation period
MOST PATIENTS WILL NOT REQUIRE AN FDO1,2
MOST PATIENTS WILL NOT
REQUIRE AN FDO1,2
Regular ophthalmic follow-ups for patients with a history
of diabetes or uveitis1
Regular follow-up ophthalmic
evaluations are recommended
Regular ophthalmic follow-ups for patients with a history
of diabetes or uveitis1
Regular follow-up ophthalmic
evaluations are recommended
Initial and periodic skin examinations for patients
taking MAYZENT1
Skin examination at the start of treatment and periodically is recommended
Obtain a baseline skin examination prior to or shortly after initiation of MAYZENT and periodically thereafter
Initial and periodic skin examinations
for patients taking MAYZENT1
Skin examination at the start of
treatment and periodically is
recommended
Obtain a baseline skin examination
prior to or shortly after initiation of
MAYZENT and periodically thereafter
A 4- OR 5-DAY TITRATION REGIMEN HELPS PATIENTS REACH THEIR MAINTENANCE DOSE
MAYZENT is an S1P receptor modulator with precisely determined dosing to fit your patient’s distinct metabolism, as well as a tailored titration schedule to help patients safely reach their appropriate maintenance dose.1

MAYZENT 0.25 mg, 1 mg, and 2 mg tablets may be stored at room temperature between 68°F to 77°F for up to 3 months. Do not refrigerate after opening.
For more information on treatment initiation, please see the Alongside™ MAYZENT
Onboarding Brochure
DOWNLOAD
DID YOU KNOW?
Like most routine lab work, genotype testing is a blood test that determines the appropriate dose for MAYZENT. Check the ‘Genotype CYP2C9’ box on the Start Form when prescribing, and Novartis will help take care of the rest—even covering the cost of testing for your eligible patients.1
DID YOU KNOW?
Like most routine lab work, genotype testing is a blood test that determines the appropriate dose for MAYZENT. Check the ‘Genotype CYP2C9’ box on the Start Form when prescribing, and Novartis will help take care of the rest—even covering the cost of testing for your eligible patients.1
Additional considerations1
-
If treatment reinitiation is required, repeat assessments and FDO as needed
-
For patients who are taking antineoplastic, immunosuppressive, or immune-modulating therapies, or who have previously used these types of medications, consider the potential unintended additive immunosuppressive effects before initiating treatment with MAYZENT
-
Determine whether patients are taking drugs that could slow heart rate or AV conduction
-
Avoid the administration of live attenuated vaccines during treatment, and for 4 weeks after stopping treatment
-
For patients with a CYP2C9*1/*3 or *2/*3 genotype, the recommended maintenance dosage is 1 mg daily starting on Day 5. MAYZENT should not be used in patients with a CYP2C9*3/*3 genotype
GET PATIENTS STARTED ON MAYZENT®
AV, atrioventricular; BPM, beats per minute; CBC, complete blood count; ECG, electrocardiogram; FDO, first-dose observation; HR, heart rate; LFT, liver function test; S1P, sphingosine 1-phosphate; VZV, varicella zoster virus.
References: 1. Mayzent [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp. 2. Data on file. Mayzent FDO Analysis. Novartis Pharmaceuticals Corp; March 2022.